Merck & Co., Inc. logo

Merck & Co., Inc. (MRK)

Market Closed
17 Jun, 20:00
NYSE NYSE
$
115. 44
+0.27
+0.2344%
$
294.03B Market Cap
58.39 P/E Ratio
0.77% Div Yield
6.81M Volume
1.46 Eps
$ 115.17
Previous Close
Add Transaction
Day Range
114.02 115.99
Year Range
76.66 125.14
Want to track MRK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Zacks | 10 months ago
Why Merck (MRK) is a Top Value Stock for the Long-Term

Why Merck (MRK) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 10 months ago
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 10 months ago
Income Strategy: I'm Buying 2 Elite Mispriced Dividends

Income Strategy: I'm Buying 2 Elite Mispriced Dividends

In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories of capital returns to shareholders. Both appear to be severely mispriced, offering enterprising investors the opportunity to capture value before the market pendulum swings back.

Seekingalpha | 10 months ago
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?

Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Zacks | 10 months ago
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript

Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.

Seekingalpha | 10 months ago
Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings

Here's What Key Metrics Tell Us About Merck (MRK) Q2 Earnings

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 10 months ago
Merck will lay off employees and shed some real estate to cut $3 billion in costs

Merck will lay off employees and shed some real estate to cut $3 billion in costs

Merck's stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.

Marketwatch | 10 months ago
Merck (MRK) Tops Q2 Earnings Estimates

Merck (MRK) Tops Q2 Earnings Estimates

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.28 per share a year ago.

Zacks | 10 months ago
Merck to Lay Off Workers and Narrows Guidance as Earnings Fall

Merck to Lay Off Workers and Narrows Guidance as Earnings Fall

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.

Wsj | 10 months ago
Sell Merck Stock Ahead Of Its Upcoming Earnings?

Sell Merck Stock Ahead Of Its Upcoming Earnings?

Merck (NYSE:MRK) is set to reveal its earnings on Tuesday, July 29, 2025. Historically, MRK stock has exhibited a trend of negative one-day returns following earnings announcements.

Forbes | 10 months ago
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.

Zacks | 10 months ago
Loading...
Load More